chrisvoncsefalvay/vaers-outcomes huggingface dataset:
blisters on both hands; This spontaneous case was reported by a consumer and describes the occurrence of BLISTER (blisters on both hands) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included METOPROLOL for Hypertension, VALSARTAN for an unknown indication.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, the patient experienced BLISTER (blisters on both hands). The patient was treated with AMOXICILLIN at an unspecified dose and frequency. On 25-Mar-2021, BLISTER (blisters on both hands) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The blisters lasted for one month until the patient got her 2nd dose. After the second dose She took Amoxicillin for the dental treatment and that took all the blisters away.   This case was linked to MOD-2021-207418.
sweet & salty taste on my tongue; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 15Nov2021 (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DYSGEUSIA (non-serious) with onset 2021, outcome "unknown", described as "sweet & salty taste on my tongue".  Additional information: the patient received the Pfizer COVID vaccine on 15Nov2021. Beginning the day after, the patient had a sweet & salty taste on tongue/in mouth ever since. The patient no longer drunk water due to the awful taste in mouth and have had to turn to unhealthy alternatives (soda) to get liquids in.  The lot number for bnt162b2 was not provided and will be requested during follow-up.
2nd dose administered 4/10, Pt now presenting with diffuse macro-papular rash to upper torso and extremities, peripheral edema, resipiratory distress, tachypneic, tachcardia. r/o Sepsis
Body aches; Long sleep; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body aches) and SOMNOLENCE (Long sleep) in a 94-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013M20A and 026L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no medical history provided).   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosae. On 05-Feb-2021, the patient experienced PAIN (Body aches) and SOMNOLENCE (Long sleep). At the time of the report, PAIN (Body aches) and SOMNOLENCE (Long sleep) outcome was unknown.            no treatment provided no concomitant medication given   Most recent FOLLOW-UP information incorporated above includes: On 05-Feb-2021: No specific follow-up information recorded.
Vomiting , pain in chest which migrated to left shoulder.  Across my back to right shoulder.
PT STATES SWELLING UNDER EYES BEGAN 10 MINS AFTER VACCNIE ADMINISTERED. NO SIGNS OF DISTRESS NOTED.  PT DENIES SOB, CHEST PAIN, DIZZINESS.  ADMINISTERED BENADRYL 25MG PO X 1 DOSE.  PT OBSERVED X 60 MINS AFTER MEDICATION ADMINISTERED.  PT STABLE AND SWELLING REDUCED UNDER EYES.
Vaccine was'nt combined with powder; Pt only received suspension; This case was reported by a other health professional via interactive digital media and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 15-NOV-2022 Reporter's Comment: This case was reported by a healthcare provider via interactive digital media. The vaccine was administered to a patient without combining lyophilized varicella zoster virus glycoprotein E (gE) antigen component (powder). The patient only received the suspension. The reporter asked what were the recommendations for repeat dosing. Additional supportive information: The vaccine was administered to a patient without combining lyophilized varicella zoster virus glycoprotein E (gE) antigen component, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The follow-up would not possible, as no contact, details were available.
Narrative: A 57yo female On September 18, 2020 a PCC nurse reported the patient had an influenza vaccine induced historical ADR of urticaria, fever and lip swelling which influenza virus vaccine injection the patient received and when was not specified
Breakthrough COVID . Patient fully vaccinated with booster. Patient is 74 yo F who came to ED with c/o SOB, cough and chills for a few days.  ED workup inluded EKG of afib with BBB, supplemental oxygen, IV abx, IV fluids. Treated for Covid Pneumonia with sepsis, COPD exacerbation.
sore arm; tiredness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 68 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 04Feb2021 16:00 (Lot number: EN5318) at the age of 68 years as dose 1, single for covid-19 immunisation. Family history included: "Meniere's syndrome" (unspecified if ongoing); "Vertigo" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 05Feb2021, outcome "recovered" (27Feb2021), described as "sore arm"; FATIGUE (non-serious) with onset 05Feb2021, outcome "recovered" (09Mar2021), described as "tiredness".  Additional information: The patient received both doses of the Pfizer-BioNTech COVID-19 Vaccine (First dose last 04Feb2021 and Second dose on 25Feb2021), reported to have various side effects: Dose 1: sore arm, tiredness & Dose 2: sore arm, tiredness, minor chills, headache, and vertigo. The patient mentioned she had no other medications. She was asking for her vertigo when its going to go away because she mentioned that 6 days after the second dose it was still there. The patient stated that she just got some side effects and is wondering if they will go away; they are not bad but and they seem to be going away. Adds they are just minor side effects. She received the first dose of the Pfizer COVID 19 vaccine on 04Feb2021 at 1600PM in the left arm. The next day she had a sore arm; and tiredness; these effects resolved after a day or so. She received the second dose of the Pfizer COVID 19 vaccine on 25Feb2021 at 16:00PM in the left arm. Again the next day she had a sore arm; and tiredness. Then she had minor chills and a slight headache that resolved in a day or so. Then she started to have episodes of vertigo on day six and that worried her. It did happened many times during the day whenever she would turn her head or get up or sit down. She has had the vertigo everyday since from 04Mar2021 to today although it seems to be getting less. Mentioned she is very healthy and does not take any medications. Pfizer COVID 19 vaccine; treatment first dose 4Feb2021/second dose 25Feb2021;Lot for second dose is EN6202. Time the Vaccination Was Given: 04Feb2021 at 16:00PM/25Feb2021 at 16:00PM. No History of all previous immunization with the Pfizer vaccine considered as suspect. No Additional Vaccines Administered on Same Date of the Pfizer Suspect. The adverse events did not require a visit to physician or ER. The patient had no prior Vaccinations (within 4 weeks), no Medical History (including any illness at time of vaccination). She reported that her mother had vertigo in her 70's due to Meniere's syndrome of the inner ear.  No follow-up attempts are possible. No further information is expected.
no adverse event, gave wrong flu shot. Pt got HD flu but was supposed to get regular flu shot. NO adverse effects noted.
This case was reported by a nurse via call center representative and described the occurrence of wrong vaccine administered in a adolescent male patient who received INFANRIX (batch number UNKNOWN, expiry date unknown). In August 2014, the patient received INFANRIX. On an unknown date, the dose was an unknown dose. In August 2014, an unknown time after receiving INFANRIX, the patient experienced wrong vaccine administered and inappropriate age at vaccine administration. On an unknown date, the outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown. It was unknown if the reporter considered the wrong vaccine administered and inappropriate age at vaccine administration to be related to INFANRIX. Additional information: Nurse reported to GSK Account Manager that a 10 to 11 year old  male inadvertently received INFANRIX instead of BOOSTRIX. The nurse noted to the account manager that the color coding on the syringes is very close shades of green. The mother of the child was contacted and no reactions were reported. Product was administered via injection at a dose of 0.5ml but the specific arm for site was unknown.
Patient felt dizzy and numbness in left arm & left leg following the administration of H1N1 vaccine IM. Patient observed & rested for 45 minutes. Given juice. Symptoms resolved and patient went to lunch and then back to class.
pt recv vax 13FEB97 & 5AUG97 & 29SEP97 lab eval revealed negative varicella zoster IgG antibody 0.12 IV
weakness, fatigue, had a bad taste in her mouth as soon as she got the vax, shortness of breath, chills,  was losing her balance, headaches, temporal artery on right side of her head is bothering her, diagnosed with gastroparesis, right arm/near breast is sore, developed tremors
2/16/23  About 10:30 she was sitting in her chair and said her heart felt funny. We went to the Emergency Room, and she was admitted for Atrial Fibrillation. She was in the hospital for at least three days and got her heart rate straightened. A  baseline pacemaker was placed. Her medications were changed.  Indapamide was discontinued. Additional Metoprolol was added and Eliquis was added.   She has been home until last week when she had more problems with fluid retention from when she was hospitalized before. She was hospitalized on 3/20/23 for three days.  A more powerful diuretic, Bumex, was added. The fluid retention is resolving.
Pt received vaccination on 7/2/15 she states 7/4/15 in AM, injection site was pink and swollen.
Employee received Influenza vaccine at approx. 1200 PM on 8/27/14 in the Employee Health Service office. He developed a swollen upper lip and mild itching sensation approx. 3 1/2-4 hrs after receiving the vaccination. He was treated with an antihistamine and given an ice pack.
Reporting administration error.   We contacted Pfizer for expiration dates, pfizer vaccine specialist advised that the expiration dates are deemed viable at the time of vaccine administration.  Pfizer vaccine vials only include manufacturer dates on the box and vials. Therefore, we contacted  pfizer to obtain expirations dates directly from them.   No adverse reactions reported from the patient at the time of the vaccination.  No adverse reaction reported since the administration of vaccination.
Swollen axillary lymph node. It started about 6 days after first dose. I should probably say sore not swollen.; Swollen axillary lymph node. It started about 6 days after first dose. I should probably say sore not swollen.; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 12:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high, recently under control. Concomitant medications included nicotine (NICORETTE) from an unknown date for an unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 the patient experienced swollen axillary lymph node. It started about 6 days after first dose. Reported she should probably say sore not swollen. Patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events lymph node pain, lymphadenopathy axillary was not recovered at the time of reporting.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. On 03-AUG-2016, the patient was vaccinated with improperly stored dose of M-M-R II lot# L029266 (dose and route of administration were not reported). This is one of several reports received from the same source. Additional information has been requested.
Patient received Pfizer dose after having already received Janssen. Patient reported no previous COVID vaccine to clinic that provided Pfizer, and vaccine system was unable to check registry to verify this.
Vertigo; Numbness on both hands; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2589) via an unspecified route of administration in the arm left on 08Oct2021 at 16:00 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis. The patient did not have known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included malus spp. vinegar extract (APPLE CIDER VINEGAR), bariatric multivitamin (MANUFACTURER UNKNOWN) and iron (MANUFACTURER UNKNOWN) all from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 3U1358A) via an unspecified route of administration in the left arm on an unknown date in Sep2021 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. On 08Oct2021 at 16:00, the patient experienced vertigo and numbness on both hands. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events vertigo and numbness on both hands was resolved with sequelae on an unknown date in Oct2021.
12x16cm area of warmth, redness, tenderness-quite tense but not indurated;
Client received Moderna first dose, due to clinic error received Pfizer second dose. Client is aware.
mild local inflammation about 5cm diameter;warm to touch, raised, redness;pt c/o sl pain to touch;
This spontaneous report was received from a registered nurse and refers to an unspecified number patients of unknown age and gender. On an unknown dates the patients may have been vaccinated with unknown number of improperly stored PROQUAD of lot # M0155698, expiry: 26-SEP-2017 after temperature excursion of 26 hours, 48 minutes to a maximum of 13.5 Fahrenheit (F). This lot had no previous excursions. In addition the reporter stated that on an unknown date, the patients may have been vaccinated with improperly stored doses of PROQUAD of lot#: M004889, expiry: 25-JUL-2017 and lot#: M009746 expiry: 23-AUG-2017 for which excursion occurred for 26 hours, 48 minutes to a maximum temperature of 13.5 F. Multiple Prior excursion for unspecified vaccine were reported of 3 hours 49 minutes to a maximum of 7.9 F, 28 F for 4.5 hours, 9.9 F for 8 hours 47 minutes, 12.4 F for 17 hours 40 minutes, 16.2 F for 17 hours 33 minutes and 14.8 F for 10 hours and 14 minutes. There were no adverse effects reported.  No additional information available. This is one of two reports received from the same source. Additional information has been requested.
Information has been received from a healthcare worker referring to multiple, unspecified number of patients (age and gender were not reported). On unspecified dates the patients were vaccinated with improperly stored doses of ROTATEQ lot # K017576, expiration date 12-JUN-2016, orally (dose, dose # and application site were not reported). No adverse effects reported. This is one of several reports received from the same source. Additional information has been requested.
Patient reported to the emergency department on 11/10/2021 with multiple neurological symptoms including paresthesis, weakness, ataxic gait, pain, and headache with symptoms prior to admission starting 11/06/2021. Patient was admitted to the ICU with Acute Inflammatory Demylenating Polyradiculopathy (AIDP). Treatment included gabapentin and IVIG treatment 11/11/2021 - 11/16/2021. Patient intubated from  11/15/2021-11/19/2021. Additional treatment included PLEX (plasmapheresis) therapy 11/16/2021-11/23/2021 . Patient was discharged to an acute rehabilitation facility on 12/1/21. Noted doing well clinically with ongoing weakness.
This spontaneous report as received from a consumer refers to her son a 14 months old male patient with drug allergy of BACTRIM and no pertinent medical history. The patient was vaccinated with first dose of both M-M-R II (Lot#, dose/frequency and route unspecified) and VARIVAX (Merck) (Lot#, dose/frequency and route unspecified) on 19-APR-2012 and second dose of both with Lot#, dose/frequency and route unspecified on 12-JUL-2012. No concomitant medication was used. On 22-JUL-2012 the patient started to develop a high fever up to 103F and swollen glands in his neck that continued to persist and has not recovered. The patient had sought medical attention via contacting physician. No lab diagnostics studies performed and no treatment was given for AE. The outcome was reported as not recovered/not resolved. Additional information has been requested.
Information has been received from a medical assistant concerning a 18 year old patient with unspecified drug reactions/allergies, "bone disorder and immunocompromised" who in April 2008, was vaccinated with a first dose of GARDASIL (route, dose and lot number not reported). In "June 2008" the patient was vaccinated IM with 0.5 ml second dose of GARDASIL (lot number not reported). There was no concomitant medication. There was no adverse effect after first dose. The medical assistant reported that the patient developed "dry bumps across her forehead", "one week after the second dose of GARDASIL". The patient has been taking BENADRYL (manufacturer/description unknown). At the time of the report the outcome of the patient was recovering. The patient sought unspecified medical attention. The medical assistant contacted during telephone follow-up could not supply the following information: dates of vaccination/therapy, dose number, lot and date of event. Additional information has been requested.
After vaccination, employee went to the monitoring area.  Around 1450, he complained of nausea and then began to vomit.  He then began to c/o flushing, itching, headache, chest tightness, and SOB.  Symptoms began approximately 10 min. after immunization. V/S: 126/82; pulse 103; resp 20; O2 sat 99% on RA; pupils equal and reactive.  Dr. was notified and assessed the employee.  Dr. ordered Benadryl 50mg IM at 1455.  This was administed by RN to Left Arm.  At 1505, FSBS was 87; O2 sat 98% on RA, pulse 97.  At 1510, O2 sat was 98% on RA; pulse 90.  At 1520, O2 sat was 98% on RA and pulse 98.  Employee continued to vomit.  Lungs were clear upon assessment.  Skin was pink.  At 1528, employee reported that the symptoms were about the same...maybe waxing and waning.  Dr. ordered Zofran 4mg SL which was administered at 1528.  At 1530, O2 sat was 98% on RA; pulse was 90; B/P was 122/90.  At 1540, O2 sat was 96% on RA; pulse 88 - rechecked on Right hand which gave a reading of O2 sat of 98% on RA; pulse 94.  At 1545, employee reported improvement of headache, itching, chest tightness, flushing, and SOB; however, was still vomiting almost coninuously.  At 1550, O2 sat was 99% on RA; pulse 83.  At 1600, B/P was 118/84; pulse 78; resp 20; O2 sat 98% on RA.  He continued to vomit.  At 1613, employee was taken via wheelchair to private vehicle of a friend and was taken to ER for evaluation.
Case number PHEH2012US025518 is an initial spontaneous report received from a physician via Astellas on 28 Dec 2012. This case refers to a 48-year-old male patient. His medical history included of metastatic prostate cancer (castration resistant). His concomitant medications included of LUPRON, XGEVA, OXYCONTIN, VICODIN, PRILOSEC, EFFEXOR, ASA, multivitamins and FLOMAX. He was vaccinated with a flu vaccine (manufacturer and batch number: not reported) on 22 Oct 2012. On the same day, he was started treatment with XTANDI capsule 40 mg, 160 mg daily for metastatic prostate cancer. On 22 Oct 2012, after starting treatment with XTANDI and post flu vaccination he developed hives. Treatment with XTANDI was stopped within one week after starting the therapy. On an unspecified date, he had recovered from hives completely. On 02 Nov 2012, treatment with XTANDI was restarted and he did not experience hives. The reporting physician assessed the causality as not related for the event and XTANDI and felt that the hives was secondary to the flu shot. No other information was available at the time of this report.
The second dose was not as bad; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (The second dose was not as bad) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in November 2020.   In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (The second dose was not as bad). At the time of the report, VACCINATION COMPLICATION (The second dose was not as bad) outcome was unknown. Not Provided          No concomitant medication was reported by reporter. No treatment medication was reported by reporter.   This case was linked to MOD-2021-319058 (Patient Link).   Reporter did not allow further contact
Youth passed out 10 minutes after receiving vaccine.  Youth reports not anxious.  Has passed out in years past.  Youth came too within minutes (1-3 minutes).
LOOSE BOWLS VOMITING AND LOSE  OF CONSONESS. PARTICAL LOOSE OF VISION.